Verici Dx (VRCI) Competitors

Verici Dx logo
GBX 0.18 -0.01 (-3.78%)
As of 11/20/2026 08:19 AM Eastern

VRCI vs. ABDX, YGEN, GDR, AGL, and GENI

Should you buy Verici Dx stock or one of its competitors? Verici Dx's main competitors and comparable companies include Abingdon Health (ABDX), Yourgene Health (YGEN), genedrive (GDR), ANGLE (AGL), and GENinCode (GENI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Verici Dx compare to Abingdon Health?

Verici Dx (LON:VRCI) and Abingdon Health (LON:ABDX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Verici Dx has a beta of 1.222, indicating that its share price is 22% more volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.132, indicating that its share price is 87% less volatile than the broader market.

Abingdon Health has higher revenue and earnings than Verici Dx. Abingdon Health is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verici Dx£3.52M3.37-£6.56M£0.101.78
Abingdon Health£10.99M3.30-£796.37K-£0.51N/A

9.9% of Verici Dx shares are held by institutional investors. Comparatively, 0.8% of Abingdon Health shares are held by institutional investors. 1.1% of Verici Dx shares are held by insiders. Comparatively, 5.4% of Abingdon Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Abingdon Health has a net margin of -19.36% compared to Verici Dx's net margin of -223.60%. Abingdon Health's return on equity of -34.31% beat Verici Dx's return on equity.

Company Net Margins Return on Equity Return on Assets
Verici Dx-223.60% -127.57% -26.14%
Abingdon Health -19.36%-34.31%-17.93%

In the previous week, Verici Dx's average media sentiment score of 0.00 equaled Abingdon Health'saverage media sentiment score.

Company Overall Sentiment
Verici Dx Neutral
Abingdon Health Neutral

Summary

Abingdon Health beats Verici Dx on 6 of the 11 factors compared between the two stocks.

How does Verici Dx compare to Yourgene Health?

Verici Dx (LON:VRCI) and Yourgene Health (LON:YGEN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Verici Dx has higher earnings, but lower revenue than Yourgene Health. Yourgene Health is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verici Dx£3.52M3.37-£6.56M£0.101.78
Yourgene Health£29.67M0.00-£8.17M-£0.01N/A

Yourgene Health has a net margin of -27.55% compared to Verici Dx's net margin of -223.60%. Yourgene Health's return on equity of -27.06% beat Verici Dx's return on equity.

Company Net Margins Return on Equity Return on Assets
Verici Dx-223.60% -127.57% -26.14%
Yourgene Health -27.55%-27.06%-6.71%

Verici Dx has a beta of 1.222, meaning that its share price is 22% more volatile than the broader market. Comparatively, Yourgene Health has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

9.9% of Verici Dx shares are held by institutional investors. Comparatively, 23.3% of Yourgene Health shares are held by institutional investors. 1.1% of Verici Dx shares are held by company insiders. Comparatively, 64.4% of Yourgene Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Verici Dx's average media sentiment score of 0.00 equaled Yourgene Health'saverage media sentiment score.

Company Overall Sentiment
Verici Dx Neutral
Yourgene Health Neutral

Summary

Yourgene Health beats Verici Dx on 6 of the 10 factors compared between the two stocks.

How does Verici Dx compare to genedrive?

genedrive (LON:GDR) and Verici Dx (LON:VRCI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, genedrive's average media sentiment score of 0.67 beat Verici Dx's score of 0.00 indicating that genedrive is being referred to more favorably in the media.

Company Overall Sentiment
genedrive Positive
Verici Dx Neutral

genedrive has a beta of 1.004, indicating that its stock price is 0% more volatile than the broader market. Comparatively, Verici Dx has a beta of 1.222, indicating that its stock price is 22% more volatile than the broader market.

Verici Dx has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
genedrive£929K14.43-£21.22M-£0.79N/A
Verici Dx£3.52M3.37-£6.56M£0.101.78

0.1% of genedrive shares are held by institutional investors. Comparatively, 9.9% of Verici Dx shares are held by institutional investors. 28.1% of genedrive shares are held by insiders. Comparatively, 1.1% of Verici Dx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Verici Dx has a net margin of -223.60% compared to genedrive's net margin of -500.75%. Verici Dx's return on equity of -127.57% beat genedrive's return on equity.

Company Net Margins Return on Equity Return on Assets
genedrive-500.75% -1,044.57% -74.09%
Verici Dx -223.60%-127.57%-26.14%

Summary

Verici Dx beats genedrive on 9 of the 12 factors compared between the two stocks.

How does Verici Dx compare to ANGLE?

Verici Dx (LON:VRCI) and ANGLE (LON:AGL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Verici Dx has a beta of 1.222, meaning that its stock price is 22% more volatile than the broader market. Comparatively, ANGLE has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market.

Verici Dx has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verici Dx£3.52M3.37-£6.56M£0.101.78
ANGLE£2.62M2.89-£21.76M-£4.80N/A

9.9% of Verici Dx shares are held by institutional investors. Comparatively, 17.5% of ANGLE shares are held by institutional investors. 1.1% of Verici Dx shares are held by company insiders. Comparatively, 2.7% of ANGLE shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Verici Dx has a net margin of -223.60% compared to ANGLE's net margin of -1,560.86%. Verici Dx's return on equity of -127.57% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
Verici Dx-223.60% -127.57% -26.14%
ANGLE -1,560.86%-157.49%-29.89%

In the previous week, Verici Dx's average media sentiment score of 0.00 equaled ANGLE'saverage media sentiment score.

Company Overall Sentiment
Verici Dx Neutral
ANGLE Neutral

Summary

Verici Dx beats ANGLE on 9 of the 11 factors compared between the two stocks.

How does Verici Dx compare to GENinCode?

GENinCode (LON:GENI) and Verici Dx (LON:VRCI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

GENinCode has a net margin of -202.42% compared to Verici Dx's net margin of -223.60%. Verici Dx's return on equity of -127.57% beat GENinCode's return on equity.

Company Net Margins Return on Equity Return on Assets
GENinCode-202.42% -481.34% -63.99%
Verici Dx -223.60%-127.57%-26.14%

2.8% of GENinCode shares are owned by institutional investors. Comparatively, 9.9% of Verici Dx shares are owned by institutional investors. 8.4% of GENinCode shares are owned by insiders. Comparatively, 1.1% of Verici Dx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, GENinCode's average media sentiment score of 0.00 equaled Verici Dx'saverage media sentiment score.

Company Overall Sentiment
GENinCode Neutral
Verici Dx Neutral

GENinCode has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.222, suggesting that its stock price is 22% more volatile than the broader market.

GENinCode has higher earnings, but lower revenue than Verici Dx. GENinCode is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GENinCode£2.60M1.62-£6.10M-£1.27N/A
Verici Dx£3.52M3.37-£6.56M£0.101.78

Summary

Verici Dx beats GENinCode on 8 of the 11 factors compared between the two stocks.

Get Verici Dx News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRCI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

VRCI vs. The Competition

MetricVerici DxLife Sciences Tools & Services IndustryHealthcare SectorLON Exchange
Market Cap£11.86M£10.69B£7.78B£2.67B
Dividend YieldN/A1.46%2.47%5.11%
P/E Ratio1.7848.9233.2222.78
Price / Sales3.378.468.104.91
Price / Cash1.3126.5521.0120.23
Price / Book0.044.194.262.40
Net Income-£6.56M£56.66B£3.50B£5.88B
1 Month Performance-21.93%-7.81%-10.48%-4.75%
1 Year Performance-76.27%11.09%-4.61%5.15%

Verici Dx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRCI
Verici Dx
N/AGBX 0.18
-3.8%
N/A-73.7%£11.86M£3.52M1.7819
ABDX
Abingdon Health
N/AGBX 9
-2.8%
N/A+19.0%£39.16M£10.99MN/A84
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67MN/A253
GDR
genedrive
N/AGBX 0.90
+1.2%
N/A-11.0%£14.37M£929KN/A43
AGL
ANGLE
N/AGBX 2.35
-11.3%
N/A+0.0%£7.58M£2.62MN/A650

Related Companies and Tools


This page (LON:VRCI) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners